

FEB 25 2014**Section 3 510(k) Summary**

This 510(k) Summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of SMDA 1990 and Title 21, CFR Section 807.92.

The assigned 510(k) Number: K133059

1. Date of Submission: 08/22/2013

2. Sponsor Identification

Wenzhou Beipu Science & Technology Co., Ltd
No.7, Jinshui Road, Wenzhou Industrial Park,
Wenzhou, Zhejiang, 325013, China

Establishment Registration Number: 3004496829

Contact Person: Xingguo Wang

Position: Sales Manager

Tel: 86 577 86651999

Fax: 86 577 86630389

Email: cnbeipu@gmail.com

3. Submission Correspondent

Ms. Diana Hong & Mr. Lee Fu

Mid-Link Consulting Co., Ltd

P.O. Box 120-119

Shanghai, 200120, China

Tel: +86-21-22815850

Fax: 240-238-7587

Email: info@mid-link.net

4. Proposed Device Identification

Proposed Device Name: Insulin Pen Needle

Proposed Device Common Name: Insulin Pen Needle

Regulatory Information:

Classification Name: Needle, Hypodermic, Single Lumen;

Classification: 2;

Product Code: FMI;

Regulation Number: 21 CFR 880.5570;

Review Panel: General Hospital;

Intended Use Statement:

The Insulin Pen Needle is intended for use with pen injector devices for the subcutaneous injection of insulin.

5. Predicate Device Identification

510(k) Number: K120690

Product Name: insulin pen needle

Manufacturer: Tiger Medical Products Ltd.

6. Device Description

The proposed device, Insulin Pen Needle, is a single-use device, which is designed for use with a pen injector for the subcutaneous injection of insulin. It consists of needle tube, hub, tube sheath, hub sheath and sealed paper. The hub can be connected screwed onto the insulin pen.

The Insulin Pen Needle is offered in various gauge sized and length.

The proposed device is available in EO sterilized to achieve a Sterility Assurance Level (SAL) of 10^{-6} .

7. Non-Clinical Test Conclusion

Non clinical tests were conducted to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:

ISO 7864 Third edition 1993-05-15, Sterile hypodermic needles for single use.

ISO 9626 First edition 1991-09-01, AMENDMENT 1 2001-06-01 Stainless steel needle tubing for the

manufacture of medical devices.

ISO 11608-2 Second edition 2012-04-01, Needle-based injection systems for medical use - Requirements and test methods - Part 2: Needles

ISO 10993-4:2002/Amd 1:2006, Biological Evaluation of Medical Device, Part 4: Selection of test for Interactions with Blood.

ISO 10993-5: 2009, Biological evaluation of medical devices -- Part 5: Tests for In Vitro cytotoxicity.

ISO 10993-7:2008(R) 2012, Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals

ISO 10993-10:2010, Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization

ISO 10993-11:2006/(R)2010, Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity.

ASTM F88/F88M-09, Standard Test Method for Seal Strength of Flexible Barrier Materials.

ISO 11737-2:2009, Sterilization of medical devices -- Microbiological methods -- Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process.

USP 35-NF30:2012, <85> Bacterial Endotoxins Test.

8. Substantially Equivalent (SE) Conclusion

The following table compares the DEVICE to the predicate device with respect to intended use, technological characteristics and principles of operation, etc.

Table 3-1 Comparison of Technology Characteristics

| Item | Proposed Device | Predicate Device |
|---------------------------|---|------------------|
| Product Code | FMI | Same |
| Regulation Number | 21 CFR 880.5570 | Same |
| Class | Class II | Same |
| Intended Use | The Insulin Pen Needle is intended for use with pen injector devices for the subcutaneous injection of insulin. | Same |
| Configuration | Needle Tube, Hub, Tube Sheath, Hub Sheath and Sealed Paper | Similar |
| Operation mode | Manual | Same |
| Needle Gauge | 29G/30G/31G/32G | Same |
| Performance specification | Comply with ISO 7864, ISO 9626, and ISO 11608-2 | Same |
| Material | Tube: 304 Stainless Steel | Same |
| | Hub: Polypropylene | Same |
| Sterilization | SAL:10 ⁻⁶ | Same |

| | | |
|---------------------|-----------------------|------|
| | EO Sterilized | Same |
| Shelf Life | 5 years | Same |
| Single Use | Yes | Same |
| Labeling and Labels | Meet FDA requirements | Same |

The proposed device, Insulin Pen Needle, is determined to be Substantially Equivalent (SE) to the predicate device, insulin pen needle (K120690), in respect of safety and effectiveness.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – W066-G609
Silver Spring, MD 20993-0002

February 25, 2014

Wenzhou Beipu Science & Technology Company, Limited
C/O Ms. Diana Hong
General Manager
Mid-Link Consulting Company, Limited
P.O. Box 120-119
Shanghai
200120 CHINA

Re: K133059
Trade/Device Name: Insulin Pen Needle
Regulation Number: 21 CFR 880.5570
Regulation Name: Hypodermic Single Lumen Needle
Regulatory Class: II
Product Code: FMI
Dated: September 22, 2013
Received: September 27, 2013

Dear Ms. Hong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Kwame O
Ulmer-S**

for

Erin I. Keith, M.S.
Acting Director
Division of Anesthesiology, General Hospital,
Respiratory, Infection Control and
Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Form Approved: OMB No. 0910-0120
Expiration Date: December 31, 2013
See PRA Statement on last page.

Indications for Use

510(k) Number (if known)
K133059

Device Name
Insulin Pen Needle

Indications for Use (Describe)
The Insulin Pen Needle is intended for use with pen injector devices for the subcutaneous injection of insulin.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)



Digitally signed by
Richard C. Chapman
Date: 2014.02.25
13:00:02 -05'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."